


**Product Name** : ER-464195-01  
**Cat. No.** : PC-35072  
**CAS No.** : 859218-37-4  
**Molecular Formula** : C<sub>23</sub>H<sub>39</sub>ClN<sub>2</sub>  
**Molecular Weight** : 379.029  
**Target** : Integrin  
**Solubility** : 10 mM in DMSO



## Biological Activity

ER-464195-01 is a specific, orally active inhibitor that inhibits **Calreticulin** (CRT) binding to **integrin  $\alpha$**  subunits (ITGAs) with IC<sub>50</sub> of 0.17, 0.36, and 0.23  $\mu$ M in the interaction between CRT and ITGA  $\alpha$ 4,  $\alpha$ L, and  $\alpha$ M/ $\alpha$ 2/ $\alpha$ 5.

ER-464195-01 dose-dependently and specifically inhibits GST-fused CRT proteins binding to ITGA4 in vitro pull-down assay. ER-464195-01 inhibits the PMA-induced T cells and the fMLP-stimulated neutrophils bound to VCAM1 (IC<sub>50</sub>=0.15  $\mu$ M) and ICAM-1 (IC<sub>50</sub>=0.19  $\mu$ M), respectively.

ER-464195-01 suppresses the cell adhesion and the migration of leukocytes, prevents colitis and downregulates the expression of inflammation-related genes in DSS-treated mice, ameliorates the severity of disease in IBD mouse models.

## References

Ohkuro M, et al. *Nat Commun*. 2018 May 17;9(1):1982.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com